A case-control study on clinical outcome and risk factors associated with carbapenem resistant isolates from critical care unit at a tertiary care hospital in Gujarat
DOI:
https://doi.org/10.18203/2320-6012.ijrms20260246Keywords:
New Delhi metallo-β-lactamases, Carbapenemase producing organisms, Carbapenem resistant EnterobacteralesAbstract
Background: The increasing prevalence of carbapenemase-producing organisms (CPO) is concerning because of the rapid dissemination of carbapenemase genes. Main objectives of the work were to study the prevalence of CPO and their genes using the Xpert® Carba-R assay in bacterial isolates from critical care settings, as well as to study patient-specific risk factors and comorbidities associated with carbapenem-susceptible organisms (CSO) and carbapenem-resistant organisms (CRO).
Methods: A prospective, observational, case-control study was conducted from January 2023 to March 2024. Bacterial identification & susceptibility testing was done using VITEK® 2 Compact and Kirby-Bauer disc diffusion method. Study consisted of 100 patients (50 carbapenem-resistant cases and 50 carbapenem-susceptible controls). CRO were further studied for carbapenemase production using the Xpert® Carba-R assay test to detect the blaKPC (KPC), blaNDM (NDM), blaVIM (VIM), blaOXA-48 (OXA-48), and blaIMP (IMP) genes.
Results: Carbapenem Resistant Acinetobacter baumanii (CRAB) [40.35%] was the most common isolate, followed by Carbapenem Resistant Pseudomonas aeruginosa (CRPA) [23.95%], Carbapenem Resistant Klebsiella penumoniae (CRKP) [21.52%], and Carbapenem Resistant Escherichia coli (CREC) [15.27%]. CRKP showed the highest carbapenemase production (42%). NDM carbapenemases were most common (54%), followed by NDM + OXA-48 co-production (30%). No genes were detected in 12% of isolates. IMP, VIM, and KPC genes were not detected. Carbapenem resistance was significantly associated with male sex, lengthy hospital stays, in-situ Foley’s catheter, and multiple co-morbidities. Mortality was 14% in cases and 4% in controls (OR, 3.9; 95% CI, 0.76 to 19.83).
Conclusions: In conclusion, CRO infections were associated with multiple risk factors, longer hospital stays and higher mortality compared to CSO infections.
Metrics
References
World Health Organization. WHO bacterial priority pathogens list, 2024: Bacterial pathogens of public health importance to guide research, development and strategies to prevent and control antimicrobial resistance, 2024. Available at: https://www.who.int/publications/i/item/9789240093461. Accessed 01 December 2025.
Bush K, Fisher JF. Epidemiological expansion, structural studies, and clinical challenges of new β-lactamases from gram-negative bacteria. Ann Revi Microbiol. 2011;65(1):455-78. DOI: https://doi.org/10.1146/annurev-micro-090110-102911
Patel G, Bonomo RA. “Stormy waters ahead”: global emergence of carbapenemases. Fronti Microbiol. 2013;4:48. DOI: https://doi.org/10.3389/fmicb.2013.00048
Poirel L, Naas T, Nordmann P. Diversity, epidemiology, and genetics of class D β-lactamases. Antimicro Agent Chemother. 2010;54(1):24-38. DOI: https://doi.org/10.1128/AAC.01512-08
Carrer A, Poirel L, Yilmaz M, Akan OA, Feriha C, Cuzon G, et al. Spread of OXA-48-encoding plasmid in Turkey and beyond. Antimicro Agent Chemother. 2010;54(3):1369-73. DOI: https://doi.org/10.1128/AAC.01312-09
Tato M, Ruiz-Garbajosa P, Traczewski M, Dodgson A, McEwan A, Humphries R, et al. Multisite evaluation of Cepheid Xpert Carba-R assay for detection of carbapenemase-producing organisms in rectal swabs. J Clin Microbiol. 2016;54(7):1814-9. DOI: https://doi.org/10.1128/JCM.00341-16
Centre for Disease Control and Prevention. Facility Guidance for Control of Carbapenem-resistant Enterobacteriaceae (CRE), 2015. Available at: https://www.cdc.gov/infection-control/media/pdfs/Guidelines-CRE-Guidance-508.pdf. Accessed 01 December 2025.
Indian Council of Medical Research. Antimicrobial Resistance Research and Surveillance Network Annual report January 2022 to December 2022, 2022. Available at: https://www.icmr.gov.in/icmrobject/custom_data/pdf/resource-guidelines/AMRSN_Annual_Report_2022.pdf. Accessed 01 December 2025.
Ralte VS, Loganathan A, Manohar P, Sailo CV, Sanga Z, Ralte L, et al. The emergence of carbapenem-resistant gram-negative bacteria in Mizoram, Northeast India. Microbiol Res. 2022;13(3):342-9. DOI: https://doi.org/10.3390/microbiolres13030027
Prabhala S, Sundaresan A, Varaiya A. Prevalence and molecular characterization of carbapenem resistant gram-negative bacilli in a tertiary care hospital in Mumbai. IP Int J Med Microbiol Trop Dis. 2023;9:150-4. DOI: https://doi.org/10.18231/j.ijmmtd.2023.030
Verma G, Nayak SR, Jena S, Panda SS, Pattnaik D, Praharaj AK, et al. Prevalence of carbapenem-resistant enterobacterales, acinetobacter baumannii, and pseudomonas aeruginosa in a tertiary care hospital in eastern India: a pilot study. J Pure Appl Microbiol. 2023;17(4):2243-50. DOI: https://doi.org/10.22207/JPAM.17.4.21
Mate PH, Devi KS, Devi KM, Damrolien S, Devi NL, Devi PP. Prevalence of carbapenem resistance among Gram-negative bacteria in a tertiary care hospital in north-east India. IOSR J Dent Med Sci. 2014;13(12):56-60. DOI: https://doi.org/10.9790/0853-131235660
Das P, AnandShrutiraaj K, Ranja M, Sen S. Prevalence of carbapenem resistance and their genotypic profile among gram-negative bacteria in a tertiary care hospital in western India. Ann Pathol Labo Medi. 2021;8(5). DOI: https://doi.org/10.21276/apalm.3053
Mohan B, Hallur V, Singh G, Sandhu HK, Appannanavar SB, Taneja N. Occurrence of blaNDM-1 and absence of blaKPC genes encoding carbapenem resistance in uropathogens from a tertiary care centre from north India. Ind J Med Res. 2015;142(3):336-43. DOI: https://doi.org/10.4103/0971-5916.166601
Han R, Shi Q, Wu S, Yin D, Peng M, Dong D, et al. Dissemination of carbapenemases (KPC, NDM, OXA-48, IMP, and VIM) among carbapenem-resistant Enterobacteriaceae isolated from adult and children patients in China. Fronti Cellu Infect Microbiol. 2020;10:314. DOI: https://doi.org/10.3389/fcimb.2020.00314
Elrahem AA, El-Mashad N, Elshaer M, Ramadan H, Damiani G, Bahgat M, et al. Carbapenem resistance in Gram-negative bacteria: a hospital-based study in Egypt. Medi. 2023;59(2):285. DOI: https://doi.org/10.3390/medicina59020285
Anandan S, Damodaran S, Gopi R, Bakthavatchalam YD, Veeraraghavan B. Rapid screening for carbapenem resistant organisms: current results and future approaches. JCDR. 2015;9(9):DM01. DOI: https://doi.org/10.7860/JCDR/2015/14246.6530
Garg A, Garg J, Kumar S, Bhattacharya A, Agarwal S, Upadhyay GC. Molecular epidemiology & therapeutic options of carbapenem-resistant Gram-negative bacteria. Ind J Med Res. 2019;149(2):285-9. DOI: https://doi.org/10.4103/ijmr.IJMR_36_18
Nieto-Saucedo JR, López-Jacome LE, Franco-Cendejas R, Colín-Castro CA, Hernández-Duran M, Rivera-Garay LR, et al. Carbapenem-Resistant Gram-Negative Bacilli Characterization in a Tertiary Care Center from El Bajio, Mexico. Antibiotics. 2023;12(8):1295. DOI: https://doi.org/10.3390/antibiotics12081295
Vala MH, Hallajzadeh M, Hashemi A, Goudarzi H, Tarhani M, Tabrizi MS, Bazmi F. Detection of Ambler class A, B and D ß-lactamases among Pseudomonas aeruginosa and Acinetobacter baumannii clinical isolates from burn patients. Ann Burns Fire Disast. 2014;27(1):8.
Lascols C, Hackel M, Marshall SH, Hujer AM, Bouchillon S, Badal R, et al. Increasing prevalence and dissemination of NDM-1 metallo-β-lactamase in India: data from the SMART study (2009). J Antimicro Chemoth. 2011;66(9):1992-7. DOI: https://doi.org/10.1093/jac/dkr240
Shanthi M, Sekar UM, Arunagiri K, Bramhne HG. OXA-181 beta lactamase is not a major mediator of carbapenem resistance in Enterobacteriaceae. JCDR. 2013;7(9):1986. DOI: https://doi.org/10.7860/JCDR/2013/5884.3379
Khajuria A, Praharaj AK, Kumar M, Grover N. Emergence of Escherichia coli, co-producing NDM-1 and OXA-48 carbapenemases, in urinary isolates, at a tertiary care centre at Central India. JCDR. 2014;8(6):DC01. DOI: https://doi.org/10.7860/JCDR/2014/7952.4413
Mohanty S, Mittal G, Gaind R. Identification of carbapenemase-mediated resistance among Enterobacteriaceae bloodstream isolates: a molecular study from India. Ind J Med Microbiol. 2017;35(3):421-5. DOI: https://doi.org/10.4103/ijmm.IJMM_16_386
Verma N, Prahraj A, Mishra B, Behera B, Gupta K. Detection of carbapenemase-producing Pseudomonas aeruginosa by phenotypic and genotypic methods in a tertiary care hospital of East India. J Laborat Phys. 2019;11(04):287-91. DOI: https://doi.org/10.4103/JLP.JLP_136_19
Palacios-Baena ZR, Giannella M, Manissero D, Rodríguez-Baño J, Viale P, Lopes S, et al. Risk factors for carbapenem-resistant Gram-negative bacterial infections: a systematic review. Clin Microbiol Infect. 2021;27(2):228-35. DOI: https://doi.org/10.1016/j.cmi.2020.10.016
Sharma K, Tak V, Nag VL, Bhatia PK, Kothari N. An observational study on carbapenem-resistant Enterobacterales (CRE) colonisation and subsequent risk of infection in an adult intensive care unit (ICU) at a tertiary care hospital in India. Infect Prevent Pract. 2023;5(4):100312. DOI: https://doi.org/10.1016/j.infpip.2023.100312
Gupta P, Bollam N, Mehta Y, Sengupta S, Gandra S. Risk factors associated with carbapenem-resistant Klebsiella pneumoniae bloodstream infections in a tertiary-care hospital in India. Infect Cont Hosp Epidemiol. 2021;42(11):1418-20. DOI: https://doi.org/10.1017/ice.2020.1280
Ling ML, Tee YM, Tan SG, Amin IM, How KB, Tan KY, et al. Risk factors for acquisition of carbapenem resistant Enterobacteriaceae in an acute tertiary care hospital in Singapore. Antimicrobial resistance and infection control. 2015;4(1):1-7. DOI: https://doi.org/10.1186/s13756-015-0066-3
Patel G, Huprikar S, Factor SH, Jenkins SG, Calfee DP. Outcomes of carbapenem-resistant Klebsiella pneumoniae infection and the impact of antimicrobial and adjunctive therapies. Infect Control Hosp Epidemiol. 2008;29(12):1099-106. DOI: https://doi.org/10.1086/592412
Souli M, Galani I, Antoniadou A, Papadomichelakis E, Poulakou G, Panagea T, et al. An outbreak of infection due to β-lactamase Klebsiella pneumoniae carbapenemase 2–producing K. pneumoniae in a Greek university hospital: molecular characterization, epidemiology, and outcomes. Clin Infect Dis. 2010;50(3):364-73. DOI: https://doi.org/10.1086/649865
Falagas ME, Rafailidis PI, Kofteridis D, Virtzili S, Chelvatzoglou FC, Papaioannou V, et al. Risk factors of carbapenem-resistant Klebsiella pneumoniae infections: a matched case-control study. J Antimicro Chemoth. 2007;60(5):1124-30. DOI: https://doi.org/10.1093/jac/dkm356
Van Duin D, Kaye KS, Neuner EA, Bonomo RA. Carbapenem-resistant Enterobacteriaceae: a review of treatment and outcomes. Diagnos Microbiol Infect Dis. 2013;75(2):115-20. DOI: https://doi.org/10.1016/j.diagmicrobio.2012.11.009
Kaur A, Gandra S, Gupta P, Mehta Y, Laxminarayan R, Sengupta S. Clinical outcome of dual colistin-and carbapenem-resistant Klebsiella pneumoniae bloodstream infections: A single-center retrospective study of 75 cases in India. Ame J infect Control. 2017;45(11):1289-91. DOI: https://doi.org/10.1016/j.ajic.2017.06.028
Hari V, Prakash NP, Nath SR. Clinical spectrum and outcomes of carbapenem resistant infections in patients with acute leukaemia: A clinical study from a tertiary oncology centre in India. J Clin Oncol. 2023;41(16):e19020. DOI: https://doi.org/10.1200/JCO.2023.41.16_suppl.e19020
King M, Heil E, Kuriakose S, Bias T, Huang V, El-Beyrouty C, et al. Multicenter study of outcomes with ceftazidime-avibactam in patients with carbapenem-resistant Enterobacteriaceae infections. Antimicro Agent Chemoth. 2017;61(7):10-128. DOI: https://doi.org/10.1128/AAC.00449-17
Yang P, Chen Y, Jiang S, Shen P, Lu X, Xiao Y. Association between antibiotic consumption and the rate of carbapenem-resistant Gram-negative bacteria from China based on 153 tertiary hospitals data in 2014. Antimicrob Resist Infect Control. 2018;7(1):1-7. DOI: https://doi.org/10.1186/s13756-018-0430-1
Reyes RE, López MJ, Pérez JE, Martínez G. Description of changes in clinical outcomes following the implementation of an antibiotic stewardship program in a level IV hospital. Biomédica. 2023;43(2):244-51. DOI: https://doi.org/10.7705/biomedica.6748
Berild D, Mohseni A, Diep LM, Jensenius M, Ringertz SH. Adjustment of antibiotic treatment according to the results of blood cultures leads to decreased antibiotic use and costs. J Antimicrob Chemoth. 2006;57(2):326-30. DOI: https://doi.org/10.1093/jac/dki463
Altaf U, Saleem Z, Akhtar MF, Altowayan WM, Alqasoumi AA, Alshammari MS, et al. Using culture sensitivity reports to optimize antimicrobial therapy: findings and implications of antimicrobial stewardship activity in a hospital in Pakistan. Medicina. 2023;59(7):1237. DOI: https://doi.org/10.3390/medicina59071237
Downloads
Published
How to Cite
Issue
Section
